請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26429
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭彥彬 | |
dc.contributor.author | Chih-Lung Huang | en |
dc.contributor.author | 黃志隆 | zh_TW |
dc.date.accessioned | 2021-06-08T07:09:57Z | - |
dc.date.copyright | 2008-09-11 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-30 | |
dc.identifier.citation | Adams JM, Cory S (1998). The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-6.
Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA et al (2003). Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 22: 8271-82. Agarwal C, Tyagi A, Kaur M, Agarwal R (2007). Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 28: 1463-70. Altieri DC (2003a). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-9. Altieri DC (2003b). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54. Ambrosini G, Adida C, Altieri DC (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-21. Ashkenazi A (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420-30. Ashkenazi A, Dixit VM (1998). Death receptors: signaling and modulation. Science 281: 1305-8. Ashkenazi A, Dixit VM (1999). Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11: 255-60. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-62. Baker SJ, Reddy EP (1998). Modulation of life and death by the TNF receptor superfamily. Oncogene 17: 3261-70. Beutler B, van Huffel C (1994). Unraveling function in the TNF ligand and receptor families. Science 264: 667-8. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P et al (2000). TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2: 241-3. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ et al (1995). Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 712-7. Briskin KB, Fady C, Wang M, Lichtenstein A (1996). Apoptotic inhibition of head and neck squamous cell carcinoma cells by tumor necrosis factor alpha. Arch Otolaryngol Head Neck Surg 122: 559-63. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y (2000). Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406: 855-62. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC (2004). Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11: 915-23. Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF, Chu SC (2006). Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent Res 85: 220-5. Cheng EH, Levine B, Boise LH, Thompson CB, Hardwick JM (1996). Bax-independent inhibition of apoptosis by Bcl-XL. Nature 379: 554-6. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM (1995). FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-12. Clarke N, Germain P, Altucci L, Gronemeyer H (2004). Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med 6: 1-23. Cory S, Huang DC, Adams JM (2003). The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-607. Deep G, Oberlies NH, Kroll DJ, Agarwal R (2007). Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis 28: 1533-42. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R (2006). Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25: 1053-69. Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R (2004). Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis 25: 1459-65. Dorai T, Aggarwal BB (2004). Role of chemopreventive agents in cancer therapy. Cancer Lett 215: 129-40. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM (2007). Survivin: a promising tumor biomarker. Cancer Lett 249: 49-60. Evans T, Rosenthal ET, Youngblom J, Distel D, Hunt T (1983). Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 33: 389-96. Fanger NA, Maliszewski CR, Schooley K, Griffith TS (1999). Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190: 1155-64. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H et al (1989). Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9: 105-13. Fulda S, Debatin KM (2004). Exploiting death receptor signaling pathways for tumor therapy. Biochim Biophys Acta 1705: 27-41. Gazak R, Walterova D, Kren V (2007). Silybin and silymarin--new and emerging applications in medicine. Curr Med Chem 14: 315-38. Green DR, Kroemer G (2004). The pathophysiology of mitochondrial cell death. Science 305: 626-9. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA (1999). Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189: 1343-54. Gross A, McDonnell JM, Korsmeyer SJ (1999). BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-911. Gruss HJ, Dower SK (1995). Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 85: 3378-404. Gu M, Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R (2007). Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res 67: 3483-91. Guo M, Hay BA (1999). Cell proliferation and apoptosis. Curr Opin Cell Biol 11: 745-52. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-16. Hartwell LH, Weinert TA (1989). Checkpoints: controls that ensure the order of cell cycle events. Science 246: 629-34. Henderson PJ, Lardy HA (1970). Bongkrekic acid. An inhibitor of the adenine nucleotide translocase of mitochondria. J Biol Chem 245: 1319-26. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS (2007). Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res 143: 58-65. Hsu S, Singh B, Schuster G (2004). Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention. Oral Oncol 40: 461-73. Huang Q, Wu LJ, Tashiro S, Onodera S, Li LH, Ikejima T (2005). Silymarin augments human cervical cancer HeLa cell apoptosis via P38/JNK MAPK pathways in serum-free medium. J Asian Nat Prod Res 7: 701-9. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M et al (1991). The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-43. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA (2002). Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 113: 506-15. Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T et al (1997). Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 19: 243-53. Katiyar SK, Roy AM, Baliga MS (2005). Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol Cancer Ther 4: 207-16. Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K et al (1999). Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 162: 2639-47. Kim EH, Kim SU, Shin DY, Choi KS (2004). Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23: 446-56. Kim H, Kim EH, Eom YW, Kim WH, Kwon TK, Lee SJ et al (2006). Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res 66: 1740-50. Kirkin V, Joos S, Zornig M (2004). The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644: 229-49. Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P et al (2001). Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276: 46639-46. Ko YC, Chiang TA, Chang SJ, Hsieh SF (1992). Prevalence of betel quid chewing habit in Taiwan and related sociodemographic factors. J Oral Pathol Med 21: 261-4. Koga Y, Matsuzaki A, Suminoe A, Hattori H, Hara T (2004). Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res 64: 1037-43. Ku JH, Kwak C, Lee HS, Park HK, Lee E, Lee SE (2004). Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 171: 631-5. Kwon B, Youn BS, Kwon BS (1999). Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes. Curr Opin Immunol 11: 340-5. Li H, Zhu H, Xu CJ, Yuan J (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501. Li J, Meyer AN, Donoghue DJ (1997). Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation. Proc Natl Acad Sci U S A 94: 502-7. Li LY, Luo X, Wang X (2001). Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412: 95-9. Li M, Ciu JR, Ye Y, Min JM, Zhang LH, Wang K et al (2002). Antitumor activity of Z-ajoene, a natural compound purified from garlic: antimitotic and microtubule-interaction properties. Carcinogenesis 23: 573-9. Lippman SM, Sudbo J, Hong WK (2005). Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 23: 346-56. Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996). Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86: 147-57. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY (2004). Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 96: 1769-80. Loro LL, Vintermyr OK, Johannessen AC (2003). Cell death regulation in oral squamous cell carcinoma: methodological considerations and clinical significance. J Oral Pathol Med 32: 125-38. Lu CD, Altieri DC, Tanigawa N (1998). Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58: 1808-12. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-90. Mao L, Hong WK, Papadimitrakopoulou VA (2004). Focus on head and neck cancer. Cancer Cell 5: 311-6. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA et al (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-805. Miyashita T, Reed JC (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-9. Murray AW (2004). Recycling the cell cycle: cyclins revisited. Cell 116: 221-34. Nakano K, Vousden KH (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-94. Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H (2000). Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 192: 1373-80. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-8. Ohnishi K, Ota I, Takahashi A, Yane K, Matsumoto H, Ohnishi T (2002). Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck. Apoptosis 7: 367-72. Ota I, Ohnishi K, Takahashi A, Yane K, Kanata H, Miyahara H et al (2000). Transfection with mutant p53 gene inhibits heat-induced apoptosis in a head and neck cell line of human squamous cell carcinoma. Int J Radiat Oncol Biol Phys 47: 495-501. Packham G, Stevenson FK (2005). Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 114: 441-9. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H (1997). Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277: 1501-5. Polverini PJ, Nor JE (1999). Apoptosis and predisposition to oral cancer. Crit Rev Oral Biol Med 10: 139-52. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE et al (2001). Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293: 1829-32. Reed JC, Jurgensmeier JM, Matsuyama S (1998). Bcl-2 family proteins and mitochondria. Biochim Biophys Acta 1366: 127-37. Rossi D, Gaidano G (2003). Messengers of cell death: apoptotic signaling in health and disease. Haematologica 88: 212-8. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R (2007). p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 6: 2696-707. Saunders MW, Birchall MA (1998). Apoptosis, matters of life and death. J Laryngol Otol 112: 822-6. Schmitz I, Walczak H, Krammer PH, Peter ME (1999). Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ 6: 821-2. Schneider P, Tschopp J (2000). Apoptosis induced by death receptors. Pharm Acta Helv 74: 281-6. Schultz IJ, Witjes JA, Swinkels DW, de Kok JB (2006). Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin. Clin Chim Acta 368: 20-32. Seta C, Fujita M, Muraki Y, Fukuda J, Kobayashi S, Haneji T (2000). Fas expression and Fas monoclonal antibody-induced apoptosis in a human squamous cell carcinoma cell line, SCC-25. J Oral Pathol Med 29: 271-8. Sharma G, Singh RP, Chan DC, Agarwal R (2003). Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res 23: 2649-55. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-21. Shimizu S, Narita M, Tsujimoto Y (1999). Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399: 483-7. Shin DM, Charuruks N, Lippman SM, Lee JJ, Ro JY, Hong WK et al (2001a). p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev 10: 603-9. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI et al (2001b). An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 1117-23. Shiu MN, Chen TH, Chang SH, Hahn LJ (2000). Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. Br J Cancer 82: 1871-4. Singh BB, Chandler FW, Jr., Whitaker SB, Forbes-Nelson AE (1998). Immunohistochemical evaluation of bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85: 692-8. Singh RP, Agarwal R (2004a). A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat Res 555: 21-32. Singh RP, Agarwal R (2004b). Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 4: 1-11. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM et al (2006). Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 98: 846-55. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R (2005). Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24: 1188-202. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R (2002). Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 62: 3063-9. Singh RP, Gu M, Agarwal R (2008a). Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 68: 2043-50. Singh RP, Tyagi A, Sharma G, Mohan S, Agarwal R (2008b). Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res 14: 300-8. Son YG, Kim EH, Kim JY, Kim SU, Kwon TK, Yoon AR et al (2007). Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res 67: 8274-84. Speiser DE, Sebzda E, Ohteki T, Bachmann MF, Pfeffer K, Mak TW et al (1996). Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol 26: 3055-60. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H (2002). Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. Embo J 21: 4520-30. Sudbo J, Bryne M, Mao L, Lotan R, Reith A, Kildal W et al (2003). Molecular based treatment of oral cancer. Oral Oncol 39: 749-58. Sun SY, Hail N, Jr., Lotan R (2004). Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 96: 662-72. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM et al (1999). Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-6. Thornberry NA, Lazebnik Y (1998). Caspases: enemies within. Science 281: 1312-6. Toyoshima F, Moriguchi T, Wada A, Fukuda M, Nishida E (1998). Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint. Embo J 17: 2728-35. Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R (2004). Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 25: 1711-20. Tyagi A, Singh RP, Agarwal C, Agarwal R (2006). Silibinin activates p53-caspase 2 pathway and causes caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: evidence for a regulatory loop between p53 and caspase 2. Carcinogenesis 27: 2269-80. Tyagi AK, Agarwal C, Singh RP, Shroyer KR, Glode LM, Agarwal R (2003). Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochem Biophys Res Commun 312: 1178-84. Van Geelen CM, de Vries EG, de Jong S (2004). Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7: 345-58. van Loo G, Schotte P, van Gurp M, Demol H, Hoorelbeke B, Gevaert K et al (2001). Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Differ 8: 1136-42. van Loo G, van Gurp M, Depuydt B, Srinivasula SM, Rodriguez I, Alnemri ES et al (2002). The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ 9: 20-6. Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R (2005). Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res 11: 8441-8. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993). Head and neck cancer. N Engl J Med 328: 184-94. Walczak H, Krammer PH (2000). The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256: 58-66. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP (1999). Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17: 331-67. Wang S, El-Deiry WS (2003). TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-33. Wang X (2001). The expanding role of mitochondria in apoptosis. Genes Dev 15: 2922-33. Wu X, Lippman SM, Lee JJ, Zhu Y, Wei QV, Thomas M et al (2002). Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res 62: 2813-8. Wyllie AH, Beattie GJ, Hargreaves AD (1981). Chromatin changes in apoptosis. Histochem J 13: 681-92. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K (2004). TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-83. Yang SH, Lin JK, Chen WS, Chiu JH (2003). Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. J Surg Res 113: 133-8. Ziaee SA, Moula SJ, Hosseini Moghaddam SM, Eskandar-Shiri D (2006). Diagnosis of bladder cancer by urine survivin, an inhibitor of apoptosis: a preliminary report. Urol J 3: 150-3. Zou H, Li Y, Liu X, Wang X (1999). An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274: 11549-56. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26429 | - |
dc.description.abstract | 根據行政院衛生署民國95 年統計資料,口腔癌已成為台灣男性十大癌症發生率的第五位,且發生率和死亡率都有逐年增加的趨勢,目前已經成為年增率最高的癌症。儘管近年來在診斷及治療技術上有進步,但口腔癌病人存活率依舊沒有顯著的改善,因此迫切需要有新的療法來解決。先前我們發現在口腔上皮變異及口腔癌有survivin基因的過度表現,但正常口腔上皮組織卻無表現。最近研究發現, silibinin 可以抑制許多種癌細胞的 survivin 表現,因此silibinin或許可做為未來治療口腔癌的潛力新藥物。本研究以人類口腔癌細胞株 SAS 及 Ca9-22 來探討 silibinin 對口腔癌細胞的影響,並進一步了解其可能的機制。 結果顯示, 150 與300 μM silibinin 處理 SAS 及 Ca9-22 細胞可以明顯抑制 survivin 的表現。 此外,以150與300 μM silibinin 處理 SAS 及 Ca9-22 細胞 24 及 48 小時, 可以明顯抑制其細胞生長,且濃度愈高或作用時間愈長,抑制效應就愈明顯 (48小時 IC50 分別為150 μM 和275 μM )。藉由流式細胞儀分析細胞之細胞週期結果顯示,以 150 與 300 μM silibinin 處理 SAS 及 Ca9-22 細胞株 48 小時後,會明顯增加 G1 期細胞數目百分比。 在西方墨點法分析中, silibinin 會增加 SAS 與 Ca9-22 細胞 PARP cleavage 表現量上升,可見得 silibinin 也可引起人類口腔癌細胞的細胞凋亡。
我們在 Ca9-22 和 SAS 細胞中加入 caspase-8 和 -9 的抑制劑(Z-LEHD-FMK, Z-IETD-FMK),發現皆可降低 silibinin 誘導的細胞凋亡現象發生,顯示 silibinin 可以活化內在和外在兩條不同的細胞死亡路徑。西方墨點法實驗中, silibinin 會增加 SAS 與 Ca9-22 細胞中 DR5, p-FADD 與 Bax 蛋白質的表現量,且活化 caspase-8 和 caspase-9,並造成 cyto-c 的釋放。 我們進一步將 SAS,Ca9-22 細胞前處理抗氧化劑 N-acetylcysteine ( NAC ) 後可降低 silibinin 所誘發的細胞凋亡反應,顯示自由基(ROS)在 silibinin 引起的人類口腔癌細胞細胞凋亡中扮演了重要的角色。另外,利用20 ng 的 TRAIL與 150 μM 的 silibinin 共同處理細胞,發現在 24 小時就有大量的PARP 被蛋白裂解,以流式細胞儀分析可發現其造成細胞凋亡的能力具有加成的效果。初步顯示 silibinin 在未來口腔癌治療與預防是具有潛力的。未來仍需要再以更精確的動物實驗及臨床試驗作更深入的評估其抗癌的功效。 | zh_TW |
dc.description.abstract | Oral cancer is the fifth leading cause of cancer-related deaths in male population in Taiwan. Despite recent advances in radiotherapy and chemotherapy, the survival of patients with oral cancer has not improved significantly. Continued investigation of new chemotherapeutic agents is in urgent need.
Our recent studies have shown that survivin is overexpressed in oral cancer, but not in normal tissues. It have shown that silibinin, a flavonoid isolated from Silybum marianum, inhibits survivin expression in various human cancer cell lines. We also found silibinin inhibited survivin expression in human oral cancer cell lines SAS and Ca9-22, supporting the idea that silibinin might develop as a specific strategy for cancer treatment. We further investigated the effects and mechanisms of silibinin on SAS and Ca9-22 cells. Silibinin significantly inhibited the proliferation of SAS and Ca9-22 cells in a dose-dependent manner compared to normal oral mucosal fibroblasts. Flow cytometric analysis of DNA content showed that silibinin treatment induced apoptosis following G1 arrest. Western blotting showed silibinin treatment induced DR5, FADD, Bax, caspase-8, -9 activation and cytochrome C released . Silibinin-induced apoptosis was also inhibited by caspase 8 inhibitor (Z-LEHD-FMK) or caspase 9 inhibitor (Z-IETD-FMK) in SAS and Ca9-22 cells. The result showed that silibinin-induced apoptosis by activating intrinsic- and extrinsic-apoptosis pathway. Pretreatment of cells with N-acetyl cysteine ( NAC ) inhibibited the increase of DR5, Bax expression and PARP cleavage. ROS played an important role for silibinin-induced apoptosis. We further evaluated the potential synergistic effect of silibinin and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in OSCC cell lines. Compared with either TRAIL (20 ng/ml ) or silibinin (150 μM)treated alone, co-administration of both drugs synergistrically induces apoptosis in both SAS and Ca9-22 cell lines. Our results indicated that silibinin sensitizes OSCC cells to TRAIL-mediated apoptosis. This may be regarded as a novel strategy for treatment of OSCC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T07:09:57Z (GMT). No. of bitstreams: 1 ntu-97-R95450002-1.pdf: 3905343 bytes, checksum: 839073d87fe222185e3fe6c7392c5179 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 中文摘要..............................................iii
英文摘要..............................................iv 目錄..................................................vi 第一章 導論 ..........................................1 1-1、口腔癌.......................................1 1-2、口腔癌之發生與腫瘤的發展過程.................2 1-3、細胞凋亡.....................................2 1-4、細胞凋亡之分子機制...........................3 1-5、Bcl-2基因家族................................6 1-6、TNF receptors和death receptors...............8 1-7、細胞週期.....................................11 1-8、 Survivin 與口腔癌之標的治療.................13 1-9、Silibinin藥物與其應用........................15 第二章 實驗材料與方法 ( Material and Method ) ........20 2-1、細胞株培養...................................20 2-2、細胞存活率試驗 ( MTT ) assay.................20 2-3、西方墨點法-細胞蛋白質的測定..................20 2-4、Caspase抑制作用..............................21 2-5、分析細胞質內的cytochrome c...................22 2-6、Cell death detection ELISA...................22 2-7、TdT-mediated dUTP-biotin nick end labeling (TUNEL )與 propidium iodide ( PI )染色................22 2-8、利用 survivin shRNA Knockdown survivin 表現..23 2-9、統計分析.....................................23 第三章 實驗結果.......................................24 3-1、Silibinin抑制SAS和Ca9-22細胞生長.............24 3-2、Silibinin誘導細胞凋亡反應....................25 3-3、Silibinin抑制 survivin 表現..................26 3-4、Silibinin 經由內在與外在凋亡路徑誘發口腔癌細胞凋亡....................................................26 3-5、Silibinin 誘導外生性細胞凋亡機制.............27 3-6、Silibinin 誘導內生性細胞凋亡機制.............28 3-7、Silibinin 對 ROS ( reactive oxygen species ) 之影響....................................................29 3-8、Silibinin 與 TRAIL 藥物加乘作用的探討........30 3-9、抑制 FasL 對於 silibinin 誘導 SAS 細胞細胞凋亡的影響....................................................31 第四章 討論...........................................67 第五章 參考文獻.......................................72 | |
dc.language.iso | zh-TW | |
dc.title | Silibinin 誘導人類口腔癌細胞凋亡機轉之研究 | zh_TW |
dc.title | Silibinin induced growth arrest and apoptosis in oral cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 郭生興 | |
dc.contributor.oralexamcommittee | 蕭宏昇 | |
dc.subject.keyword | 口腔癌,silibinin,survivin,細胞凋亡, | zh_TW |
dc.subject.keyword | oral cancer,silibinin,survivin,apoptosis, | en |
dc.relation.page | 84 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2008-08-01 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 3.81 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。